GSK’s Jempreli (dostarlimab) + CT Receives EC’s Approval to Treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
Shots:
- The EC has approved Jemperli + carboplatin-paclitaxel to treat dMMR/MSI-H primary advanced/recurrent endometrial cancer. This also converts its previous conditional approval into full approval for the same post-progression on a Pt-containing regimen
- The approval was based on part 1 of the P-III (RUBY) study assessing dostarlimab + carboplatin-paclitaxel followed by dostarlimab vs PBO. Part 2 assesses dostarlimab + carboplatin-paclitaxel followed by dostarlimab + niraparib vs PBO for primary advanced/recurrent endometrial cancer
- Results with a median follow-up of ≥25mos. showed a PFS of 72% with Jemperli added to CT. In a prespecified exploratory analysis for OS in the dMMR/MSI-H population, Jemperli with CT resulted in a 70% reduction in the risk of death vs CT
Ref: GSK | Image: GSK
Related News:- GSK Receives the EMA’s CHMP Positive Opinion of Jemperli (dostarlimab) for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
